Tech Company Financing Transactions
Highland Therapeutics Funding Round
Highland Therapeutics closed a $6.7 million funding round on 8/21/2013. Backers included Clinical Development Group and private investors.
Transaction Overview
Company Name
Announced On
8/21/2013
Transaction Type
Venture Equity
Amount
$6,700,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to conduct up to five clinical studies with its two lead compounds, HLD-100 (a novel formulation of amphetamine) and HLD-200 (a novel formulation of methylphenidate), both being developed to treat the symptoms associated with Attention, Deficit /Hyperactivity Disorder (ADHD), further market research and manufacuring scale-up.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
101 College St. 200
Toronto ON, M5G 1L7
Canada
Toronto ON, M5G 1L7
Canada
Phone
Website
Email Address
Not Recorded
Overview
At Highland Therapeutics we strive to create meaningful improvements in everyday life with innovations that go beyond simple convenience.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Lickrish
Chief Financial Officer
Nelson Isabel
Browse more venture capital transactions:
Prev: 8/21/2013: InstaMed venture capital transaction
Next: 8/21/2013: IPG venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs